US FDA Approves 5-in-1 Meningococcal Vaccine, CDC's Approval Pending

GSK plc recently announced its MenABCWY vaccine PENMENVY could simplify meningococcal vaccination delivery and help protect more U.S. adolescents against these five common disease-causing serogroups – A, B, C, W, and Y, which commonly cause invasive meningococcal disease (IMD)/

To help realize that goal, the U.S. Food and Drug Administration has approved PENMENVY for use in individuals aged 10 through 25 years.

The vaccine combines the antigenic components of GSK's meningococcal vaccines, BEXSERO (Meningococcal Group B Vaccine) and MENVEO (Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine).

Tony Wood, GSK's chief scientific officer, said in a February 14, 2025 press release, "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by serogroup B."

"Building on our global leadership in meningococcal vaccination and our longstanding commitment to addressing unmet needs in disease prevention, we aim to help protect more teens and young adults at a life stage when they are at an increased risk."

A positive vote on PENMENVY's use is expected at the U.S. CDC's Advisory Committee on Immunization Practices meeting on February 26, 2025.